Protara Therapeutics CEO Jesse Shefferman disposes of 215,687 common shares for $882,156.83PUBT·Jul 1 at 03:11 PMTARA-4.96%
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Studybenzinga_article·May 15 at 10:36 AMTARA-4.96%SBIO-2.76%
Oppenheimer Keeps Their Buy Rating on Protara Therapeutics (TARA)Tip Ranks·May 14 at 09:06 AMTARA-4.96%IBBQ-2.30%
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on ThursdayMarket Beat·May 7 at 03:06 AMTARA-4.96%FBT-3.24%
JonesTrading Remains a Buy on Protara Therapeutics (TARA)Tip Ranks·Apr 6 at 03:38 PMSBIO-2.76%XLV-0.54%
Protara Therapeutics Highlights Positive TARA-002 Phase 2 ResultsTip Ranks·Mar 30 at 08:19 AMIBBQ-2.30%SBIO-2.76%
